SINGLE CYCLE SIV PARTICLES NOVEL VACCINE STRATEGY
SINGLE CYCLE SIV PARTICLES NOVEL VACCINE STRATEGY
批准号:
6116185
负责人:
Linqi Zhang
金额:
$5.31万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-05-01 至 2000-04-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Our goal in this proposal is to construct and test a single-cycle
SIV (SC-SIV) particle as a source of antigen for generating and
maximizing an immune response against SIV infection in the rhesus
macaque. The unique characteristic of this novel strategy is that
viral replication is only allowed to undergo a single cycle, thereby
avoiding the potential risks associated with an inactivated whole
virus vaccine or a live attenuated virus vaccine. In addition, this
single-cycle nature of replication allows a certain degree of de novo
synthesis of viral proteins once the particle enters target cells,
thereby allowing stimulation of cytotoxic T lymphocytes (CTLs) in
vivo. This type of vaccine candidate is therefore particularly
appealing because it most closely resembles the live attenuated virus
vaccine that provides a high degree of protection against SIV
infection in macaques, while eliminating the risks associated with
persistent viral replication. By multiple introductions of this
single-cycle particle into rhesus macaques, it is hoped that the
particles will generate an immune response that would sufficiently
mimic in magnitude and spectrum the protective responses observed in
macaques infected by the SIVmac239?nef and SIVmac239?3 viruses.
Allowing de novo synthesis of viral proteins while limiting viral
spread from the infected cell is therefore the central component of
this new vaccine strategy. Dendritic Cells (DCs) are specialized
antigen presenting cells and are also potent initiators and
stimulators of the immune system. Recent developments have made it
possible to isolate large numbers of pure DCs directly from peripheral
blood mononuclear cells. Taking advantage of these new developments,
we will include DCs in our immunization regimen to increase the
Infectivity and antigenicity of SC-SIV. SIV-specific humoral and CTL
responses will be studied to evaluate the effectiveness of this novel
vaccine and immunization strategy. FUNDING NIH (R21 AI42669)
PUBLICATIONS None
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Proteomic and Functional Profile of HIV Positive Saliva
-
批准号:7668035
-
项目类别:
-
资助金额:$25.97万
-
财政年份:2008
-
负责人:Linqi Zhang
-
依托单位:
The Proteomic and Functional Profile of HIV Positive Saliva
-
批准号:7291223
-
项目类别:
-
资助金额:$26.83万
-
财政年份:2007
-
负责人:Linqi Zhang
-
依托单位:
DEFINING SALIVA PROTEIN IN NORMAL RHESUS MACAQUES USING PROTEINCHIP TECHNOLOGY
-
批准号:7349711
-
项目类别:
-
资助金额:$2.48万
-
财政年份:2006
-
负责人:Linqi Zhang
-
依托单位:
A Novel Model for the Study of Lung Pathogenesis of SARS
-
批准号:7227734
-
项目类别:
-
资助金额:$62.75万
-
财政年份:2005
-
负责人:Linqi Zhang
-
依托单位:
A Novel Model for the Study of Lung Pathogenesis of SARS
-
批准号:7414820
-
项目类别:
-
资助金额:$62.0万
-
财政年份:2005
-
负责人:Linqi Zhang
-
依托单位:
EVALUATION OF REPLICATION-COMPETENT SINGLE-CYCLE SIV
-
批准号:6939829
-
项目类别:
-
资助金额:$6.15万
-
财政年份:2003
-
负责人:Linqi Zhang
-
依托单位:
CONTRIBUTION OF THE THYMUS TO SIV PATHOGENESIS
-
批准号:6632226
-
项目类别:
-
资助金额:$46.73万
-
财政年份:2000
-
负责人:Linqi Zhang
-
依托单位:
CONTRIBUTION OF THE THYMUS TO SIV PATHOGENESIS
-
批准号:6511212
-
项目类别:
-
资助金额:$51.99万
-
财政年份:2000
-
负责人:Linqi Zhang
-
依托单位:
CONTRIBUTION OF THE THYMUS TO SIV PATHOGENESIS
-
批准号:6374415
-
项目类别:
-
资助金额:$46.7万
-
财政年份:2000
-
负责人:Linqi Zhang
-
依托单位:
CONTRIBUTION OF THE THYMUS TO SIV PATHOGENESIS
-
批准号:6149687
-
项目类别:
-
资助金额:$43.41万
-
财政年份:2000
-
负责人:Linqi Zhang
-
依托单位:
SINGLE CYCLE SIV PARTICLES--A NOVEL VACCINE STRATEGY
-
批准号:2555223
-
项目类别:
-
资助金额:$24.75万
-
财政年份:1997
-
负责人:Linqi Zhang
-
依托单位:
SINGLE CYCLE SIV PARTICLES--A NOVEL VACCINE STRATEGY
-
批准号:2673198
-
项目类别:
-
资助金额:$24.75万
-
财政年份:1997
-
负责人:Linqi Zhang
-
依托单位:
The Proteomic and Functional Profile of HIV Positive Saliva
-
批准号:8291143
-
项目类别:
-
资助金额:$27.04万
-
财政年份:--
-
负责人:Linqi Zhang
-
依托单位:
The Proteomic and Functional Profile of HIV Positive Saliva
-
批准号:8116972
-
项目类别:
-
资助金额:$27.43万
-
财政年份:--
-
负责人:Linqi Zhang
-
依托单位:
The Proteomic and Functional Profile of HIV Positive Saliva
-
批准号:7904310
-
项目类别:
-
资助金额:$26.75万
-
财政年份:--
-
负责人:Linqi Zhang
-
依托单位:
海外基金